Supernus Pharmaceuticals, Inc. (SUPN) is gaining ground in pre-market trading on Tuesday. The advance comes after the company received a tentative approval letter from the FDA for Trokendi XR, a once-daily extended release formulation of topiramate.
Shares of Supernus are up $1.78, or 31.2%, to $7.49.
The letter stated that the FDA completed its review of the Trokendi XR NDA and that no additional clinical trials are required. Supernus said its initial understanding is that final approval is conditioned on resolving a marketing exclusivity issue raised by the FDA regarding a specific pediatric population.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.